Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews
暂无分享,去创建一个
K. Webber | S. Pearson | H. Gurney | C. Vajdic | M. V. van Leeuwen | S. Luu | Soojung Hong | Martin Brown | G. Delaney | Lee Hunt | Sallie-Anne Pearson
[1] Bi-Cheng Wang,et al. Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis , 2019, The Annals of pharmacotherapy.
[2] O. Franco,et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research , 2019, European Journal of Epidemiology.
[3] Livia Puljak,et al. Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks , 2019, BMC medical research methodology.
[4] Shenhong Wu,et al. Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis , 2019, Cancer investigation.
[5] M. Page,et al. Evaluation of Reproducible Research Practices in Oncology Systematic Reviews With Meta-analyses Referenced by National Comprehensive Cancer Network Guidelines. , 2019, JAMA oncology.
[6] T. Reungwetwattana,et al. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis , 2019, Expert review of clinical pharmacology.
[7] Shenhong Wu,et al. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis , 2019, Clinical Hypertension.
[8] M. Schuler,et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. , 2019, International journal of cardiology.
[9] He-long Zhang,et al. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis , 2019, Therapeutics and clinical risk management.
[10] W. Hilgers,et al. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study , 2019, BMC Cancer.
[11] B. Godman,et al. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis , 2018, BioDrugs.
[12] Na-Lin Lai,et al. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials , 2018, BMC Cancer.
[13] International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.
[14] J. Gu,et al. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials , 2018, Clinical Drug Investigation.
[15] K. Bhaskaran,et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review , 2018, British medical journal.
[16] Kihyun Kim,et al. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone , 2018, International Journal of Hematology.
[17] B. Zhang,et al. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials , 2018, OncoTargets and therapy.
[18] Q. Hu,et al. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis , 2018, Japanese journal of clinical oncology.
[19] A. Manolis,et al. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1 , 2018, Expert opinion on drug safety.
[20] W. Guan,et al. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. , 2018, Journal of thoracic disease.
[21] J. Raduà,et al. Ten simple rules for conducting umbrella reviews , 2018, Evidence-Based Mental Health.
[22] K. Webber,et al. Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews , 2018, BMJ Open.
[23] Lifen Zheng,et al. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer , 2018, International Journal of Gynecologic Cancer.
[24] A. Guddati. Current and potential targets for drug design in the androgen receptor pathway for prostate cancer , 2018, Expert opinion on drug discovery.
[25] Rifang Liao,et al. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis , 2018, Expert review of anticancer therapy.
[26] D. Schadendorf,et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients , 2018, European journal of preventive cardiology.
[27] Tingting Liu,et al. The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis , 2017, Oncotarget.
[28] Zhang Yan,et al. Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection , 2017, Oncotarget.
[29] G. Tortora,et al. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer , 2017, Clinical genitourinary cancer.
[30] M. Parmar,et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis , 2017, European journal of cancer.
[31] Xinqiang Han,et al. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy , 2017, npj Precision Oncology.
[32] A. Capucci,et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. , 2017, Cancer treatment reviews.
[33] T. Choueiri,et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials , 2017, Oncotarget.
[34] M. Totzeck,et al. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients , 2017, Journal of the American Heart Association.
[35] Jing Ye,et al. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis . , 2017, International journal of clinical pharmacology and therapeutics.
[36] Pauline Campbell,et al. Selecting and implementing overview methods: implications from five exemplar overviews , 2017, Systematic Reviews.
[37] G. Wei,et al. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis , 2017, Cancer Chemotherapy and Pharmacology.
[38] Wei-min Yao,et al. Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[39] Zhihong Liu,et al. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis , 2017, Oncotarget.
[40] D. Generali,et al. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis , 2017, Investigational New Drugs.
[41] Paul Montgomery,et al. Risk of bias in overviews of reviews: a scoping review of methodological guidance and four‐item checklist , 2017, Research synthesis methods.
[42] J. Ioannidis. Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews , 2017, British Journal of Sports Medicine.
[43] Xiangyuan Wu,et al. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review , 2017, Oncotarget.
[44] Gang Zhang,et al. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials , 2017, Oncotarget.
[45] S. Suissa,et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] Z. Mei,et al. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. , 2016, Clinics and research in hepatology and gastroenterology.
[47] E. Yeh,et al. Oncocardiology-Past, Present, and Future: A Review. , 2016, JAMA cardiology.
[48] L. Stewart,et al. Systematic review and meta‐analysis of the risk of severe and life‐threatening thromboembolism in cancer patients receiving anti‐EGFR monoclonal antibodies (cetuximab or panitumumab) , 2016, International journal of cancer.
[49] Lin Shui,et al. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials , 2016, Oncotarget.
[50] Yuanyuan Zhang,et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients , 2016, Oncotarget.
[51] J. Ioannidis. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. , 2016, The Milbank quarterly.
[52] O. Clark,et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis , 2016, BMC Cancer.
[53] H. Elhalawani,et al. Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data , 2016, Clinical and Translational Oncology.
[54] L. Elting,et al. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents , 2016, Supportive Care in Cancer.
[55] Fares Alahdab,et al. New evidence pyramid , 2016, Evidence-Based Medicine.
[56] J. Guo,et al. Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. , 2016, American health & drug benefits.
[57] D. Generali,et al. Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. , 2016, Critical reviews in oncology/hematology.
[58] W. Zhong,et al. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. , 2016, The oncologist.
[59] R. Xu,et al. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials , 2016, OncoTargets and therapy.
[60] N. Agarwal,et al. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential , 2016, Therapeutic advances in medical oncology.
[61] S. Fu,et al. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. , 2016, Journal of cancer research and therapeutics.
[62] Michael L. Wang,et al. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. , 2016, Journal of the National Cancer Institute.
[63] Linwei Wang,et al. Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis , 2016, Experimental and therapeutic medicine.
[64] Shufeng Zhou,et al. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review , 2016, Hepatology International.
[65] Bao-yuan Li,et al. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis , 2016, Chinese medical journal.
[66] John P A Ioannidis,et al. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. , 2016, Parkinsonism & related disorders.
[67] Xiaojing Yan,et al. Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis , 2016, BioMed research international.
[68] M. Gasparri,et al. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials , 2015, Oncotarget.
[69] Qin Li,et al. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials , 2015, Scientific Reports.
[70] H. Leung,et al. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data , 2015, Expert opinion on drug safety.
[71] Rongzhong Huang,et al. Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis , 2015, Scientific Reports.
[72] D. Steensma,et al. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. , 2015, Journal of the American College of Cardiology.
[73] A. Abdollahi,et al. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2015, PloS one.
[74] Hanan Khalil,et al. systematic reviews : methodological development , conduct and reporting of an umbrella review approach , 2015 .
[75] N. Keating,et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. , 2015, European urology.
[76] R. Iacovelli,et al. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. , 2015, European journal of cancer.
[77] Y. Ba,et al. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials , 2015, Clinical and Translational Oncology.
[78] H. Ren,et al. Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2015, Chinese medical journal.
[79] B. Prediger,et al. Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties. , 2015, Journal of clinical epidemiology.
[80] C. Qu,et al. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. , 2015, World journal of gastroenterology.
[81] Q. Hua,et al. Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis , 2015, Journal of chemotherapy.
[82] J. Adolfsson,et al. Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis , 2015, PloS one.
[83] J. Ioannidis,et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses , 2015, The Lancet Neurology.
[84] B. Xiong,et al. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials , 2015, Tumor Biology.
[85] Yunzhao Zhao,et al. Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies , 2015, Clinical Drug Investigation.
[86] Jie-tao Ma,et al. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis , 2015, Medical Oncology.
[87] A. Russo,et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy , 2015, Expert opinion on drug safety.
[88] Chuang Chen,et al. Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials , 2015, Oncology letters.
[89] Feng Xu,et al. An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma , 2014, PloS one.
[90] O. Abdel-Rahman,et al. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. , 2014, Critical reviews in oncology/hematology.
[91] Dawid Pieper,et al. Up-to-dateness of reviews is often neglected in overviews: a systematic review. , 2014, Journal of clinical epidemiology.
[92] Jinyao Ning,et al. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials , 2014, Tumor Biology.
[93] Wenjie Zhu,et al. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials , 2014, Medical Oncology.
[94] O. Abdel-Rahman,et al. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. , 2014, Future oncology.
[95] T. Choueiri,et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors , 2014, British Journal of Cancer.
[96] Yang Yao,et al. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. , 2014, Critical reviews in oncology/hematology.
[97] Yang Yao,et al. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials , 2014, British journal of clinical pharmacology.
[98] M. Page,et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. , 2014, The Cochrane database of systematic reviews.
[99] Shaona Niu,et al. Bortezomib and lenalidomide as front-line therapy for multiple myeloma , 2014, Leukemia & lymphoma.
[100] S. Fu,et al. Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups , 2014, Clinical Drug Investigation.
[101] G. Han,et al. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis , 2014, Molecular Biology Reports.
[102] Bing-kun Xiao,et al. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[103] Q. Mei,et al. Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials , 2014, Tumor Biology.
[104] Xing-Lin Chen,et al. Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis , 2014, PloS one.
[105] P. Bie,et al. Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis , 2014, PloS one.
[106] L. Moja,et al. Trastuzumab-containing regimens for metastatic breast cancer. , 2014, The Cochrane database of systematic reviews.
[107] T. Choueiri,et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. , 2014, Critical reviews in oncology/hematology.
[108] Qi Zhang,et al. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis , 2014, Journal of Cancer Research and Clinical Oncology.
[109] A. Jurczyszyn,et al. Bortezomib for the treatment of multiple myeloma , 2014, Expert review of hematology.
[110] W. Lei,et al. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. , 2014, Indian journal of cancer.
[111] Q. Lv,et al. Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis , 2014, Journal of breast cancer.
[112] Y. Liu,et al. The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis , 2014, Contemporary oncology.
[113] Yang Yao,et al. Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis , 2014, Clinical Drug Investigation.
[114] J. P. Chen,et al. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[115] K. O'Byrne,et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. , 2014, Lung cancer.
[116] Yunpeng Liu,et al. Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis , 2013, PloS one.
[117] F. Vera-Badillo,et al. Fulvestrant for advanced breast cancer: a meta-analysis. , 2013, Cancer treatment reviews.
[118] R. Liu,et al. A Systematic Review of Sorafenib in Child-Pugh A Patients With Unresectable Hepatocellular Carcinoma , 2013, Journal of clinical gastroenterology.
[119] J. Xu,et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis , 2013, European Journal of Clinical Pharmacology.
[120] O. Clark,et al. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis , 2013, Core evidence.
[121] Hang-cheng Zhou,et al. Chemotherapy with or without gefitinib in patients with advanced non‐small‐cell lung cancer: a meta‐analysis of 6844 patients , 2013, Chinese medical journal.
[122] Yang Yao,et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. , 2013, British journal of clinical pharmacology.
[123] Zhangwei Yang,et al. Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials , 2013, Clinical Drug Investigation.
[124] J. Cortes,et al. Cardiovascular toxicity of tyrosine kinase inhibitors , 2013, Expert opinion on drug safety.
[125] Shuodong Wu,et al. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. , 2013, Cancer biotherapy & radiopharmaceuticals.
[126] Wenping Ding,et al. Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.
[127] Xing-Lin Chen,et al. Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis , 2013, PloS one.
[128] Yang Yao,et al. Risk of venous thromboembolic events associated with VEGFR‐TKIs: A systematic review and meta‐analysis , 2013, International journal of cancer.
[129] B. Xiong,et al. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis , 2013, Journal of chemotherapy.
[130] A. Valachis,et al. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade , 2013, International journal of cancer.
[131] Bo Yang,et al. Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2013, PloS one.
[132] M. Galsky,et al. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis , 2013, Journal of Human Hypertension.
[133] Joel Morganroth,et al. Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy , 2013, Drug Safety.
[134] Yang Yao,et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials , 2013, British journal of clinical pharmacology.
[135] Hong‐Lin Chen,et al. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials , 2013, Archives of Gynecology and Obstetrics.
[136] Junmin Chen,et al. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials , 2013, Annals of Hematology.
[137] Yang Yao,et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis , 2013, Cancer Chemotherapy and Pharmacology.
[138] L. Leibovici,et al. The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review , 2013, PloS one.
[139] Dawid Pieper,et al. Overviews of reviews often have limited rigor: a systematic review. , 2012, Journal of clinical epidemiology.
[140] David Moher,et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. , 2012, The Cochrane database of systematic reviews.
[141] Z. Wang,et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.
[142] M. Piccart-Gebhart,et al. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence , 2012, Journal of oncology.
[143] A. Valachis,et al. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence , 2012, Breast Cancer Research and Treatment.
[144] Zhi Xu,et al. Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis , 2012, Anti-cancer drugs.
[145] J. Haerting,et al. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. , 2012, The Cochrane database of systematic reviews.
[146] J. Baselga,et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[147] L. Moja,et al. Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.
[148] A. Sasse,et al. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups , 2012, BMC Cancer.
[149] J. Zang,et al. Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis , 2012, PloS one.
[150] D. Moher,et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews , 2012, Systematic Reviews.
[151] Yongjian Xu,et al. Risk profile of bevacizumab in patients with non-small cell lung cancer: A meta-analysis of randomized controlled trials , 2012, Acta oncologica.
[152] A. Valachis,et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. , 2011, Breast.
[153] O. Clark,et al. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. , 2011, Lung cancer.
[154] S. Mandrekar,et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis , 2011, Leukemia.
[155] S. Mandrekar,et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis , 2011, Leukemia.
[156] T. Choueiri,et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[157] A. Sasse,et al. Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2010, PloS one.
[158] Ofer Shpilberg,et al. High‐dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients—Systematic review and meta‐analysis , 2011, American journal of hematology.
[159] T. Choueiri,et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[160] Juxiang Chen,et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. , 2011, Cancer treatment reviews.
[161] M. Aapro,et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials , 2011, Journal of experimental & clinical cancer research : CR.
[162] V. Torri,et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[163] T. Choueiri,et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[164] Shenhong Wu,et al. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. , 2011, JAMA.
[165] O. Woo,et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials , 2011, Investigational New Drugs.
[166] David Moher,et al. An international registry of systematic-review protocols , 2011, The Lancet.
[167] I. Hozo,et al. Thalidomide versus bortezomib based regimens as first‐line therapy for patients with multiple myeloma: A systematic review , 2011, American journal of hematology.
[168] U. Siebert,et al. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. , 2010, The oncologist.
[169] M. Wolf,et al. 500 ml of blood loss does not decrease non-invasive tissue oxygen saturation (StO2) as measured by near infrared spectroscopy - A hypothesis generating pilot study in healthy adult women , 2010, Journal of trauma management & outcomes.
[170] Shenhong Wu,et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. , 2010, American journal of hypertension.
[171] T. Choueiri,et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[172] A. Tan,et al. Cetuximab‐based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta‐analysis of seven randomized controlled trials , 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[173] Z. Zou,et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis , 2010, European Journal of Clinical Pharmacology.
[174] Hui Gao,et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials , 2010, Anti-cancer drugs.
[175] Shenhong Wu,et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials , 2010, Acta oncologica.
[176] J. Grimshaw,et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. , 2009, Journal of clinical epidemiology.
[177] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.
[178] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[179] J. Haerting,et al. Anti-angiogenic therapies for metastatic colorectal cancer. , 2009, The Cochrane database of systematic reviews.
[180] Z. Mo,et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer , 2009, International Journal of Colorectal Disease.
[181] K. Stergiopoulos,et al. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.
[182] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[183] A. Oxman,et al. Overviews of Reviews , 2008 .
[184] D. Reece,et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. , 2008, Cancer treatment reviews.
[185] F. Siannis,et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. , 2008, The oncologist.
[186] B. Barlogie,et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.
[187] A. Kudelka,et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.
[188] G. Viani,et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.
[189] A. Taher,et al. Thalidomide and thrombosis , 2007, Thrombosis and Haemostasis.
[190] W. Dahut,et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[191] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[192] R. Chlebowski,et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen , 2003, Journal of General Internal Medicine.
[193] J. Feyzi,et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.
[194] H. Tunstall-Pedoe,et al. Long term effects of tamoxifen on blood lipid values in breast cancer. , 1992, BMJ.
[195] D. Cescon,et al. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.
[196] Michael S. Ewer,et al. Cardiotoxicity of anticancer treatments , 2015, Nature Reviews Cardiology.
[197] X. Qu,et al. The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials , 2015, Clinical Drug Investigation.
[198] Jinfu Tu,et al. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. , 2014, Chinese medical journal.
[199] Zhi-rui Zhou,et al. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[200] Yong Song,et al. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[201] J. Pignon,et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[202] Jun Zhang,et al. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[203] J. Hou,et al. Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[204] Tianyi Zhu,et al. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[205] C. Liao,et al. A Meta‐Analysis of Randomized Controlled Trials Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Alone in HER‐2‐Positive Advanced Breast Cancer , 2011, The breast journal.
[206] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[207] P. Tugwell,et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. , 2007, BMC medical research methodology.